Back to Search
Start Over
Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients.
- Source :
-
Basic research in cardiology [Basic Res Cardiol] 2022 Mar 08; Vol. 117 (1), pp. 13. Date of Electronic Publication: 2022 Mar 08. - Publication Year :
- 2022
-
Abstract
- Cancer therapies with anthracyclines have been shown to induce cardiovascular complications. The aims of this study were to establish an in vitro induced pluripotent stem cell model (iPSC) of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and to examine whether doxorubicin (DOX)-treated ACT-iPSC cardiomyocytes (CM) can recapitulate the clinical features exhibited by patients, and thus help uncover a DOX-dependent pathomechanism. ACT-iPSC CM generated from individuals with CD20 <superscript>+</superscript> B-cell lymphoma who had received high doses of DOX and suffered cardiac dysfunction were studied and compared to control-iPSC CM from cancer survivors without cardiac symptoms. In cellular studies, ACT-iPSC CM were persistently more susceptible to DOX toxicity including augmented disorganized myofilament structure, changed mitochondrial shape, and increased apoptotic events. Consistently, ACT-iPSC CM and cardiac fibroblasts isolated from fibrotic human ACT myocardium exhibited higher DOX-dependent reactive oxygen species. In functional studies, Ca <superscript>2+</superscript> transient amplitude of ACT-iPSC CM was reduced compared to control cells, and diastolic sarcoplasmic reticulum Ca <superscript>2+</superscript> leak was DOX-dependently increased. This could be explained by overactive CaMKIIδ in ACT CM. Together with DOX-dependent augmented proarrhythmic cellular triggers and prolonged action potentials in ACT CM, this suggests a cellular link to arrhythmogenic events and contractile dysfunction especially found in ACT engineered human myocardium. CamKIIδ inhibition prevented proarrhythmic triggers in ACT. In contrast, control CM upregulated SERCA2a expression in a DOX-dependent manner, possibly to avoid heart failure conditions. In conclusion, we developed the first human patient-specific stem cell model of DOX-induced cardiac dysfunction from patients with B-cell lymphoma. Our results suggest that DOX-induced stress resulted in arrhythmogenic events associated with contractile dysfunction and finally in heart failure after persistent stress activation in ACT patients.<br /> (© 2022. The Author(s).)
- Subjects :
- Cardiotoxicity metabolism
Cardiotoxicity pathology
Doxorubicin metabolism
Doxorubicin toxicity
Humans
Myocytes, Cardiac metabolism
Heart Diseases metabolism
Heart Failure metabolism
Induced Pluripotent Stem Cells metabolism
Lymphoma, B-Cell metabolism
Lymphoma, B-Cell pathology
Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1435-1803
- Volume :
- 117
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Basic research in cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 35260914
- Full Text :
- https://doi.org/10.1007/s00395-022-00918-7